Tdap Vaccine in Post-Partum Women
This study is currently recruiting participants.
Verified February 2013 by National Institute of Allergy and Infectious Diseases (NIAID)
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT01711645
First received: October 18, 2012
Last updated: May 23, 2013
Last verified: February 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Monitoring immune response and longevity in serum and milk after Tdap administration to postpartum women. The clinical trial will involve women (aged 18 - 45 years) who have just delivered full-term infants (greater than or equal to 37 completed weeks of gestation) at Vanderbilt University Medical Center. The enrollment period will be nine months. The duration is over two years of observation.
| Condition | Intervention | Phase |
|---|---|---|
|
Tetanus Diphtheria Pertussis |
Biological: Adacel® Tdap vaccine |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Phase IV, Open Label Trial to Evaluate Immunogenicity of Tdap Vaccine in Post-Partum Women to Optimize Vaccination Schedule for Women Who May Have a Subsequent Child |
Resource links provided by NLM:
Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):
Primary Outcome Measures:
- ELISA Geometric mean fold rise by study day [ Time Frame: Prior to and following Tdap, through 24 months post-vaccination ] [ Designated as safety issue: No ]
- Kinetics of the ELISA IgG antibody rise in serum expressed in EU/ml. [ Time Frame: Prior to and following Tdap, through 24 months post-vaccination ] [ Designated as safety issue: No ]
- ELISA Geometric mean titers (GMT) of serum IgG to pertussis toxin, filamentous hemaglutinin, pertactin and fimbrae measured and assessed in EU/ml [ Time Frame: Prior to and following Tdap through 24 months post-vaccination ] [ Designated as safety issue: No ]
- Proportion of subjects with 4-fold rise in ELISA antibody concentrations [ Time Frame: Prior to and following Tdap, through 24 months post-vaccination ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- ELISA GMT of breast milk IgA to pertussis toxin, filamentous hemagluttin, pertactin and fimbrae by study day. [ Time Frame: Prior to vaccination, 2 weeks, 6 weeks, and 6 months after vaccination ] [ Designated as safety issue: No ]
- ELISA Geometric mean fold rise by study day [ Time Frame: Prior to vaccination, 2 weeks, 6 weeks, and 6 months after vaccination ] [ Designated as safety issue: No ]
- Proportion of subjects with 4-fold rise in antibody concentrations by study day. [ Time Frame: Prior to vaccination, 2 weeks, 6 weeks, and 6 months after vaccination ] [ Designated as safety issue: No ]
- Kinetics of the ELISA IgG antibody decline in breast milk expressed in EU/ml. [ Time Frame: After Tdap and at 2 weeks, 6 weeks, and 6 months after vaccination ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 55 |
| Study Start Date: | October 2012 |
| Estimated Study Completion Date: | October 2015 |
| Estimated Primary Completion Date: | October 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Adacel® Tdap vaccine
55 postpartum subjects receive a single intramuscular (IM) 0.5 mL dose of Adacel® (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed).
|
Biological: Adacel® Tdap vaccine
55 postpartum subjects receive a single intramuscular (IM) 0.5 mL dose of Adacel® (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed).
|
Detailed Description:
This is a single site, prospective study involving only one intervention, receipt of a single 0.5 mL intramuscular (IM) dose of Adacel (Tetanus toxoid, reduced diphtheria toxoid and acellular Pertussis) vaccine, among 55 healthy post partum women. The purpose of the study is to examine the immune responses and subsequent decline in serum and breast milk antibody titers over two years of observation. The clinical trial will involve women (aged 18 - 45 years) who have just delivered full-term infants (greater than or equal to 37 completed weeks of gestation) at Vanderbilt University Medical Center. One particular population at Vanderbilt to target will be the "centering prenatal care group" that has breastfeeding rates as high as 75 percent at hospital discharge and maintained at 20 percent at 6 months. The enrollment period will be nine months. The subjects, staff assessing subjects, and laboratory personnel will be aware of receipt of the vaccine. Since only a single vaccine product is being utilized, there is no blinding needed of the subjects or staff.
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Healthy, postpartum women as determined by medical history aged 18 - 45 years of age inclusive.
- Women 1-4 days postpartum from delivery of full-term infants. Full-term will be defined as estimated gestational age of greater than or equal to 37 completed weeks of pregnancy determined by menstrual dating and concordant with ultrasound findings as per ACOG bulletin #101).
- Provide written informed consent prior to initiation of any study procedures.
- Available for the entire study period.
- Able to understand and complete all relevant study procedures during study participation (women who ultimately have limited ability to breast feed after enrollment will not be excluded from the study).
Exclusion Criteria:
- Prior receipt of a tetanus or diphtheria-containing vaccine within two years of enrollment.
- Prior receipt of a tetanus and diphtheria toxoid and acellular pertussis vaccine within two years of enrollment.
- Known or suspected impairment of immunologic function.
- Febrile illness within the last 24 hours or an oral temperature >/= 100.4 degrees F (>/= 38 degrees C) at the time of enrollment.
- History of documented tetanus, diphtheria, or pertussis disease within the preceding 5 years.
- History of allergic or adverse reaction to diphtheria, tetanus, or pertussis vaccines.
- Receipt of any steroids, immunoglobulins, other blood products/transfusion within the past six months- excluding Rh immunoglobulin (Rhogam™ and Rhophylac™).
- Is enrolled or plans to enroll in another clinical trial with an investigational product while participating in this study (observational studies are allowed).
- Known active infection with HIV, hepatitis B, or hepatitis C.
- History of alcohol or drug abuse in the last 5 years.
- Any condition which, in the opinion of the investigators, may pose a health risk to the subject or interfere with the evaluation of the study objectives.
- Any woman with health condition who is currently taking glucocorticoids, i.e., oral, parenteral, and high-dose inhaled steroids, and immunosuppressive or cytotoxic drugs.
- Sensitive to latex, based on package insert
- Progressive or unstable neurologic condition, based on package insert.
- Receipt of influenza or other vaccines concomitantly administered or for 42 days following Adacel, based on package insert.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01711645
Contacts
| Contact: Kathryn M Edwards | (615) 322-3078 | kathryn.edwards@vanderbilt.edu |
Locations
| United States, Tennessee | |
| Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center | Recruiting |
| Nashville, Tennessee, United States, 37232-2573 | |
Sponsors and Collaborators
More Information
No publications provided
| Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
| ClinicalTrials.gov Identifier: | NCT01711645 History of Changes |
| Other Study ID Numbers: | 11-0035, HHSN272200800007C |
| Study First Received: | October 18, 2012 |
| Last Updated: | May 23, 2013 |
| Health Authority: | United States: Institutional Review Board United States: Federal Government United States: Food and Drug Administration |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
|
Tetanus, Diptheria toxoids, Acellular, Pertussis, Tdap, Adacel®, postpartum, women |
Additional relevant MeSH terms:
|
Hypocalcemia Diphtheria Whooping Cough Tetanus Tetany Corynebacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections Bacterial Infections Bordetella Infections Gram-Negative Bacterial Infections |
Respiratory Tract Infections Infection Respiratory Tract Diseases Clostridium Infections Neuromuscular Manifestations Neurologic Manifestations Nervous System Diseases Calcium Metabolism Disorders Metabolic Diseases Signs and Symptoms |
ClinicalTrials.gov processed this record on May 23, 2013